Form 8-K - Current report:
SEC Accession No. 0001193125-22-295957
Filing Date
2022-12-01
Accepted
2022-12-01 08:15:52
Documents
15
Period of Report
2022-11-28
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d428641d8k.htm   iXBRL 8-K 27074
2 EX-5.1 d428641dex51.htm EX-5.1 7872
6 GRAPHIC g428641dsp4.jpg GRAPHIC 3484
7 GRAPHIC g428641dsp5.jpg GRAPHIC 2030
  Complete submission text file 0001193125-22-295957.txt   174690

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rlyb-20221128.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rlyb-20221128_lab.xml EX-101.LAB 19500
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rlyb-20221128_pre.xml EX-101.PRE 12150
9 EXTRACTED XBRL INSTANCE DOCUMENT d428641d8k_htm.xml XML 3621
Mailing Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510
Business Address 234 CHURCH STREET SUITE 1020 NEW HAVEN CT 06510 203- 859-3820
Rallybio Corp (Filer) CIK: 0001739410 (see all company filings)

EIN.: 851083789 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40693 | Film No.: 221437424
SIC: 2834 Pharmaceutical Preparations